The US Food and Drug Administration appears poised to continue with a plan to ban prescription fluoride supplements at a time ...

Pharvaris is advancing deucrictibant, an oral bradykinin B2-receptor antagonist, in two late-stage trials. Read my analysis ...

United Bankshares, Inc. (NASDAQ: UBSI) ("United"), today reported record earnings for the second quarter of 2025 of $120.7 million, or $0.85 per diluted share. Second quarter of 2025 results produced ...

Detailed price information for Takeda Pharmaceutical Ltd ADR (TAK-N) from The Globe and Mail including charting and trades.

Protagonist Therapeutics, Inc.Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy ...

A 64-year-old woman presented to an outside provider with 5 days of left eye “burning, itching, redness and blurry vision” and 1 day of acute “9 out of 10” left eye pain.She had a medical history of ...

Full Year Capital Guidance Lowered; Production Guidance Increased Highlights: DENVER, /CNW/ – Ovintiv Inc. (NYSE: OVV) (TSX: OVV) (“Ovintiv” or the “Company”) today announced its ...

Cadence Bank (NYSE: CADE) (the Company), today announced financial results for the quarter ended June 30, 2025.Highlights for the ...

Get the latest ImmunityBio, Inc. (IBRX) stock news and headlines to help you in your trading and investing decisions.

News, analysis, and competitive intelligence on the biggest developments impacting the Pennsylvania legal community.

Identifying the correct uveitis type can help reveal underlying systemic infections, neoplastic conditions, and other ...